Pramoxine
Pramoxine is a surface local anesthetic of the morpholine class that blocks voltage-gated sodium channels in sensory nerve terminals, preventing the initiation and propagation of nociceptive impulses to reduce pain and pruritus. It is used topically for the temporary relief of pain, itching, and discomfort associated with minor skin irritations, hemorrhoids, and anogenital conditions.
Moleküler Ağırlık
293,4000 g/mol
LogP
3,10
TPSA
30,90 Ų
Lipinski RO5
Geçer
Etki Mekanizması
Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.
2D Yapı
Cite this structure
Embed this structure
SMILES
CCCCOc1ccc(OCCCN2CCOCC2)cc1
InChI
InChI=1S/C17H27NO3/c1-2-3-12-20-16-5-7-17(8-6-16)21-13-4-9-18-10-14-19-15-11-18/h5-8H,2-4,9-15H2,1H3
Molecular Formula
C17H27NO3
HBD / HBA
- / 4
Döndürülebilir Bağlar
9
Ağır Atomlar
21
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Pramoxine is a surface local anesthetic of the morpholine class that blocks voltage-gated sodium channels in sensory nerve terminals, preventing the initiation and propagation of nociceptive impulses to reduce pain and pruritus. It is used topically for the temporary relief of pain, itching, and discomfort associated with minor skin irritations, hemorrhoids, and anogenital conditions.
Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.
Yes, Pramoxine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1198. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 4886. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="pramoxine"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/pramoxine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/pramoxine/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/pramoxine/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="pramoxine"></drugfyi-drug>